加载中
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
常规交易时段
US$7.285
−US$0.165 · -2.21%
盘中时间采用ET。市场数据可能有所延迟。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日内区间
当前US$7.285
52周区间
当前US$7.285
盘中时间采用ET。市场数据可能有所延迟。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日内区间
当前US$7.285
52周区间
当前US$7.285
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.63亿 USD | 2.63亿 USD | 7850万 USD | 1.31亿 USD | 5360万 USD |
| 销货成本 | 520万 USD | — | — | — | — |
| 毛利 | 2.57亿 USD | 2.63亿 USD | 7850万 USD | 1.31亿 USD | 5360万 USD |
| 研究与开发 | 2.83亿 USD | 3.48亿 USD | 3.8亿 USD | 3.15亿 USD | 1.8亿 USD |
| 销售、一般及管理费用 | 8940万 USD | 1.65亿 USD | 1亿 USD | 7960万 USD | 6160万 USD |
| 营业费用 | 3.72亿 USD | 5.14亿 USD | 4.8亿 USD | 3.95亿 USD | 2.42亿 USD |
| 利息收入 | 2200万 USD | 5480万 USD | 3880万 USD | 1200万 USD | 180万 USD |
| 利息支出 | — | — | — | — | 10万 USD |
| 折旧和摊销 | 520万 USD | 660万 USD | 670万 USD | 820万 USD | 600万 USD |
| 营业利润 | −1.15亿 USD | −2.5亿 USD | −4.02亿 USD | −2.63亿 USD | −1.88亿 USD |
| 净利润 | −8080万 USD | −1.99亿 USD | −3.67亿 USD | −2.83亿 USD | −1.91亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1767.03万0.00%2.3万亿 USD0.03%US$379.99-0.27%
iShares Russell 2000 ETFIWM1177.42万0.02%785.63亿 USD0.19%US$275.29-0.87%
Vanguard Extended Market ETFVXF692.84万0.01%954亿 USD0.05%US$231.94-0.66%
State Street SPDR S&P Pharmaceuticals ETFXPH357.57万0.73%4.62亿 USD0.35%US$62.435-0.76%
Fidelity Enhanced Small Cap ETFFESM338.83万0.05%64.1亿 USD0.28%US$44.83-0.86%
iShares Biotechnology ETFIBB329.84万0.03%104.01亿 USD0.44%US$197.55-2.85%
Vanguard Russell 2000 ETFVTWO314.23万0.02%180亿 USD0.06%US$111.17-0.93%
Schwab U.S. Small-Cap ETFSCHA225.82万0.01%216.99亿 USD0.03%US$32.37-0.74%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
